OptimizeRx Corp.

OPRX Healthcare Health Information Services

OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

8.50 0.35 −3.95%
Market cap
$166.7M
P/E
35.4×
Fwd P/E
23.0×
Dividend yield
—
F-score
8/9
Altman Z
3.31
Beneish M
−2.77
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
23.83 17.44 45.41 0.00

+8 more quarters

P/S ratio
1.09 1.10 2.08 3.48
P/FCF ratio
5.79 8.12 12.11 32.93
P/Operating CF
12.48 (252.30) 32.09 118.93
P/B ratio
0.82 0.91 1.77 3.11
EV/Sales
1.04 1.13 2.10 3.56
EV/EBITDA
6.27 6.12 13.41 82.57
EV/FCF
5.51 8.34 12.24 33.68
Current Ratio
5.58 5.37 3.04 3.05
Net Debt/EBITDA
(4.06) 1.75 0.23 2.60
Debt/Equity
0.15 0.18 0.20 0.23
Earnings Yield
4.20% 5.73% 2.20% 0.00%
Free Cash Flow Yield
17.28% 12.32% 8.26% 3.04%
Free Cash Flow per Share
0.46 (0.03) 0.39 0.17
Book value per Share
6.98 6.91 6.91 6.58
Free Cash Flow
8.58 (0.49) 7.29 3.19
EV/EBIT
9.39 8.53 19.65 57.36
Other line items

Show all line items

Columns are period end dates